Ono Pharmaceutical Co., Ltd.

Symbol: 4528.T




Market price today

  • 8.4775

    P/E Ratio

  • -1.4324

    PEG Ratio

  • 1.04T

    MRK Cap

  • 0.04%

    DIV Yield

Ono Pharmaceutical Co., Ltd. (4528-T) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Mr. Gyo Sagara
Full-time employees:3761
Address:8-2, Kyutaromachi 1-chome

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

General Outlook

When we look at how much money they make before expenses, they keep 0.756% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.329%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.256%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.143% return, is a testament to Ono Pharmaceutical Co., Ltd.'s adeptness in optimizing resource deployment. Ono Pharmaceutical Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.166%. Furthermore, the proficiency of Ono Pharmaceutical Co., Ltd. in capital utilization is underscored by a remarkable 0.204% return on capital employed.

Stock Prices

Ono Pharmaceutical Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $2326, while its low point bottomed out at $2282. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Ono Pharmaceutical Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 4528.T liquidity ratios reveals its financial health of the firm. The current ratio of 394.92% gauges short-term asset coverage for liabilities. The quick ratio (318.87%) assesses immediate liquidity, while the cash ratio (113.98%) indicates cash reserves.

Current Ratio394.92%
Quick Ratio318.87%
Cash Ratio113.98%

Profitability Ratios

4528.T profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 33.42% underscores its earnings before tax deductions. The effective tax rate stands at 23.28%, revealing its tax efficiency. The net income per EBT, 76.67%, and the EBT per EBIT, 101.49%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 32.93%, we grasp its operational profitability.

Pretax Profit Margin33.42%
Effective Tax Rate23.28%
Net Income per EBT76.67%
EBT per EBIT101.49%
EBIT per Revenue32.93%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 3.95, it details the span from stock purchase to revenue. The 3 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 330.95% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding319
Days of Inventory Outstanding139
Operating Cycle249.46
Days of Payables Outstanding159
Cash Conversion Cycle90
Receivables Turnover3.31
Payables Turnover2.29
Inventory Turnover2.62
Fixed Asset Turnover4.75
Asset Turnover0.56

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 222.86, and free cash flow per share, 191.88, depict cash generation on a per-share basis. The cash per share value, 284.88, showcases liquidity position. A payout ratio of 0.29 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.21, offers insight into cash flow relative to sales.

Operating Cash Flow per Share222.86
Free Cash Flow per Share191.88
Cash per Share284.88
Payout Ratio0.29
Operating Cash Flow Sales Ratio0.21
Free Cash Flow to Operating Cash Flow Ratio0.86
Cash Flow Coverage Ratio12.35
Short Term Coverage Ratio46.80
Capital Expenditure Coverage Ratio7.19
Dividend Paid and Capex Coverage Ratio2.05

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 0.96%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.01, we discern the balance between debt and equity financing. The long-term debt to capitalization, 0.80%, and total debt to capitalization, 1.08%, ratios shed light on its capital structure. An interest coverage of 99.03 indicates its ability to manage interest expenses.

Debt Ratio0.96%
Debt Equity Ratio0.01
Long Term Debt to Capitalization0.80%
Total Debt to Capitalization1.08%
Interest Coverage99.03
Cash Flow to Debt Ratio12.35
Company Equity Multiplier1.14

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 16.84%, indicates top-line expansion, while the gross profit growth, 19.73%, reveals profitability trends. EBIT growth, 4.95%, and operating income growth, 4.95%, offer insights into operational profitability progression.

Revenue Growth16.84%
Gross Profit Growth19.73%
EBIT Growth4.95%
Operating Income Growth4.95%
EPS Growth7.33%
EPS Diluted Growth7.33%
Weighted Average Shares Growth-0.54%
Weighted Average Shares Diluted Growth-0.54%
Dividends per Share Growth23.90%
Operating Cash Flow Growth-16.42%
Free Cash Flow Growth-7.70%
10-Year Revenue Growth per Share165.35%
5-Year Revenue Growth per Share44.11%
3-Year Revenue Growth per Share29.65%
10-Year Operating CF Growth per Share321.49%
5-Year Operating CF Growth per Share310.51%
3-Year Operating CF Growth per Share-4.11%
10-Year Net Income Growth per Share256.40%
5-Year Net Income Growth per Share67.20%
3-Year Net Income Growth per Share39.66%
10-Year Shareholders Equity Growth per Share66.73%
5-Year Shareholders Equity Growth per Share30.61%
3-Year Shareholders Equity Growth per Share21.87%
10-Year Dividend per Share Growth per Share55.00%
5-Year Dividend per Share Growth per Share23.38%
3-Year Dividend per Share Growth per Share31.25%
Receivables Growth18.42%
Inventory Growth6.81%
Asset Growth-1.02%
Book Value per Share Growth3.76%
Debt Growth-2.77%
R&D Expense Growth21.63%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.38, and the price to book ratio, 1.38, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.08, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 11.36, and price to operating cash flows, 10.20, gauge market valuation against cash flow metrics.

Price Book Value Ratio1.38
Price to Book Ratio1.38
Price to Sales Ratio2.08
Price Cash Flow Ratio10.20
Price Earnings to Growth Ratio-1.43
Enterprise Value Multiple6.08
Price Fair Value1.38
Price to Operating Cash Flow Ratio10.20
Price to Free Cash Flows Ratio11.36
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Ono Pharmaceutical Co., Ltd. (4528.T) on the JPX in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 8.477 in 2024.

What is the ticker symbol of Ono Pharmaceutical Co., Ltd. stock?

The ticker symbol of Ono Pharmaceutical Co., Ltd. stock is 4528.T.

What is company IPO date?

IPO date of Ono Pharmaceutical Co., Ltd. is 2001-01-04.

What is company current share price?

Current share price is 2272.500 JPY.

What is stock market cap today?

The market cap of stock today is 1036306545345.000.

What is PEG ratio in 2024?

The current -1.432 is -1.432 in 2024.

What is the number of employees in 2024?

In 2024 the company has 3761.